Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
23 mars 2023 16h05 HE
|
Athira Pharma, Inc.
On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline data in early 2024 Continuing to advance development...
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
08 mars 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
06 mars 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
01 févr. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
31 janv. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Provides 2023 Pipeline Outlook
05 janv. 2023 07h00 HE
|
Athira Pharma, Inc.
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase...
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
21 déc. 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
05 déc. 2022 07h30 HE
|
Athira Pharma, Inc.
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS Data adds to the growing body of evidence...
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
01 déc. 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
29 nov. 2022 11h00 HE
|
Athira Pharma, Inc.
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST,...